Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
28 juil. 2023 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
[New Report] Induced Pluripotent Stem Cells Market is estimated to be US$ 3.5 billion by 2032; Growing Prevalence of Diseases and Demand for Therapies to Foster Industrial Growth - By PMI
28 juin 2023 11h05 HE
|
PMI
Covina, June 28, 2023 (GLOBE NEWSWIRE) -- “According to the latest research study, the demand of “Induced Pluripotent Stem Cells Market accounted for US$ 1.8 billion in 2022 and is estimated to be...
Fate Therapeutics to Present at Upcoming June Investor Conferences
31 mai 2023 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
03 mai 2023 16h01 HE
|
Fate Therapeutics, Inc.
Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
24 avr. 2023 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
DEADLINE ALERT for YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
20 mars 2023 12h05 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, March 20, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
13 mars 2023 12h24 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
06 mars 2023 11h50 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Fate Therapeutics to Present at Upcoming March Investor Conferences
03 mars 2023 16h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
01 mars 2023 11h34 HE
|
The Rosen Law Firm PA
NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2,...